Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Siga Technologies Inc (SIGA)

Siga Technologies Inc (SIGA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Siga Technologies Inc 31 EAST 62ND STREET NEW YORK NY 10065 USA

www.siga.com P: 212-672-9100 F: 212-697-3130

Description:

SIGA Technologies Inc. is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents and vaccines to fight potential biowarfare pathogens. With broad technology platforms in both vaccines and antibiotics, SIGA's product development programs emphasize the increasingly serious problem of drug resistant bacteria. In addition to smallpox, SIGA has antiviral programs targeting other Category A pathogens, including arenaviruses, dengue virus, and the filoviruses.

Key Statistics

Overview:

Market Capitalization, $K 604,993
Enterprise Value, $K 454,843
Shares Outstanding, K 71,092
Annual Sales, $ 139,920 K
Annual Net Income, $ 68,070 K
Last Quarter Sales, $ 116,480 K
Last Quarter Net Income, $ 72,260 K
EBIT, $ 83,620 K
EBITDA, $ 84,160 K
60-Month Beta 0.94
% of Insider Shareholders 2.17%
% of Institutional Shareholders 55.40%
Float, K 69,549
% Float 97.83%
Short Volume Ratio 0.41

Growth:

1-Year Return 42.14%
3-Year Return 14.94%
5-Year Return 57.66%
5-Year Revenue Growth -70.67%
5-Year Earnings Growth -81.37%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 1.01 on 03/12/24
Latest Earnings Date 05/02/24
Earnings Per Share ttm 0.95
EPS Growth vs. Prev Qtr 10,200.00%
EPS Growth vs. Prev Year 10,200.00%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 47.00%

SIGA Ratios

Ratio
Price/Earnings ttm 9.40
Price/Earnings forward 7.28
Price/Earnings to Growth N/A
Return-on-Equity % 44.84%
Return-on-Assets % 36.64%
Profit Margin % 48.65%
Debt/Equity 0.00
Price/Sales 4.54
Price/Cash Flow 9.20
Price/Book 3.21
Book Value/Share 2.77
Interest Coverage 4.98
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar